Literature DB >> 26123228

Development of visceral leishmaniasis in an HIV(+) patient upon immune reconstitution following the initiation of antiretroviral therapy.

Benjamin T Schleenvoigt1, Ralf Ignatius2, Michael Baier3, Thomas Schneider4, Marko Weber5, Stefan Hagel6,5, Christina Forstner6,7, Mathias W Pletz6.   

Abstract

CASE
PRESENTATION: Here, we report on a case of VL in an HIV-infected patient from the Republic of Georgia who had moved to Germany 14 years before and who had travelled several times to southern Europe in between. After presenting with typical Pneumocystis jiroveci pneumonia, which was treated appropriately, the patient was started on antiretroviral therapy. Shortly thereafter, however, he developed fever of unknown origin. All laboratory assays for the diagnosis of various infectious agents including serological assays and polymerase chain reaction testing of bone marrow aspirate to diagnose VL did not yield positive results at first. Only upon repetition of these tests, diagnosis of VL could be made and the patient treated accordingly. CASE DISCUSSION: Visceral leishmaniasis (VL) is a common opportunistic infection in HIV-positive patients from endemic countries but occurs rarely following antiretroviral treatment. This case demonstrates that patients who develop VL upon immune reconstitution may not be diagnosed initially by standard laboratory assays for the diagnosis of VL and underlines the necessity to repeat serologic and molecular biologic testing for VL in cases of fever of unknown origin in patients from or with travel history to endemic countries.

Entities:  

Keywords:  HIV infection; IRIS; Immune reconstitution inflammatory syndrome; Visceral leishmaniasis

Mesh:

Substances:

Year:  2015        PMID: 26123228     DOI: 10.1007/s15010-015-0813-7

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

Review 1.  Immune restoration disease after antiretroviral therapy.

Authors:  Martyn A French; Patricia Price; Shelley F Stone
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

2.  Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Authors:  V Pintado; P Martín-Rabadán; M L Rivera; S Moreno; E Bouza
Journal:  Medicine (Baltimore)       Date:  2001-01       Impact factor: 1.889

3.  Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.

Authors:  V Mosimann; A Neumayr; C Hatz; J A Blum
Journal:  Infection       Date:  2013-07-09       Impact factor: 3.553

4.  Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008).

Authors:  Ruth Gil-Prieto; Stefan Walter; Jorge Alvar; Angel Gil de Miguel
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

5.  Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

Authors:  R de la Rosa ; J A Pineda; J Delgado; J Macías; F Morillas; J Martín-Sánchez; M Leal; A Sánchez-Quijano; E Lissen
Journal:  Clin Infect Dis       Date:  2001-02-06       Impact factor: 9.079

Review 6.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

7.  Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.

Authors:  Rachel ter Horst; Simon M Collin; Koert Ritmeijer; Adey Bogale; Robert N Davidson
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

8.  Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis.

Authors:  Anette Chrusciak-Talhari; Rodrigo Ribeiro-Rodrigues; Carolina Talhari; Roberto Moreira Silva; Luis Carlos de Lima Ferreira; Simone Ferreira de Castro Botileiro; Lucilaide Oliveira Santos; Reynaldo Dietze; Sinésio Talhari
Journal:  Am J Trop Med Hyg       Date:  2009-10       Impact factor: 2.345

9.  Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.

Authors:  Cristina Mussini; Christian Manzardo; Margaret Johnson; Antonella d'Arminio Monforte; Caterina Uberti-Foppa; Andrea Antinori; M John Gill; Laura Sighinolfi; Vanni Borghi; Adriano Lazzarin; José M Miró; Caroline Sabin
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

10.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

View more
  3 in total

Review 1.  Leishmaniasis-HIV coinfection: current challenges.

Authors:  José Angelo Lauletta Lindoso; Mirella Alves Cunha; Igor Thiago Queiroz; Carlos Henrique Valente Moreira
Journal:  HIV AIDS (Auckl)       Date:  2016-10-07

Review 2.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16

3.  Visceral Leishmaniasis and Herpes Zoster as a Component of Syndrome of Immune Reconstitution Inflammatory Syndrome in an HIV-Positive Patient.

Authors:  Ermira Muço; Arta Karruli; Neada Hoxha; Alma Hoxhaj; Majlinda Kokici
Journal:  Case Rep Infect Dis       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.